Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.

Abstract: A display system circuitry capable of saving power consumption includes a display panel and a driver circuitry. In particular, the display panel includes a plurality of source electrodes with a plurality of data lines and a plurality of gate electrodes further includes a gate driver which is directly incorporated into a thin film transistor array to form Gate on Array (GOA) electrode, a source electrode transmitting a plurality of data driving signals, a gate electrode transmitting gate driving signals, a VCOM electrode transmitting voltage driving signals, a display electrode transmitting displaying driving signals. The driver circuitry includes a display driver IC which includes a source driver operably configured to drive the source electrode and gate control to control gate driver output, and a touch driver IC configured to generate the touch scan signal from a touch sensor.

Abstract: A display system circuitry capable of saving power consumption includes a display panel and a driver circuitry. In particular, the display panel includes a plurality of source electrodes with a plurality of data lines and a plurality of gate electrodes further includes a gate driver which is directly incorporated into a thin film transistor array to form Gate on Array (GOA) electrode, a source electrode transmitting a plurality of data driving signals, a gate electrode transmitting gate driving signals, a VCOM electrode transmitting voltage driving signals, a display electrode transmitting displaying driving signals. The driver circuitry includes a display driver IC which includes a source driver operably configured to drive the source electrode and gate control to control gate driver output, and a touch driver IC configured to generate the touch scan signal from a touch sensor.

Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.

Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.

Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.

Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.

Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.

Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.

Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.

Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.

Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.

Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.

Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.

Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.

Abstract: Disclosed herein are methods of treating arthritis, comprising administering a sustained release composition comprising liposomes comprising one or more phospholipids, cholesterol, and a therapeutic agent. The sustained release composition can be administered intraarticularly.

Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.

Abstract: A boat propeller comprises a hub formed of a front cylindrical member and a rear cylindrical member. The hub is provided in the joining place with a plurality of receiving cavities which are arranged equiangularly and circularly. Each cavity is provided removably with an angle setting member which is joined with the hub. A plurality of blades are joined with the outer periphery of the hub such that the inner ends of the blades are inserted into the cavities and are located by the angle setting members. Under the circumstance that the shapes of the hub and the blades remain unchanged, the blade pitch in relation to the hub can be changed by the angle setting members of various shapes.

Abstract: A boat propeller comprises a hub formed of a front cylindrical member and a rear cylindrical member. The hub is provided in the joining place with a plurality of receiving cavities which are arranged equiangularly and circularly. Each cavity is provided removably with an angle setting member which is joined with the hub. A plurality of blades are joined with the outer periphery of the hub such that the inner ends of the blades are inserted into the cavities and are located by the angle setting members. Under the circumstance that the shapes of the hub and the blades remain unchanged, the blade pitch in relation to the hub can be changed by the angle setting members of various shapes.